NCT02672358View on ClinicalTrials.gov

Study of Efficacy and Safety of Dabrafenib and Trametinib Combination Therapy in Japanese Patients With BRAF V600E Stage IV NSCLC

PHASE2WithdrawnINTERVENTIONAL
0
Timeline

Start Date

September 3, 2018

Primary Completion Date

September 2, 2019

Study Completion Date

December 7, 2020

Conditions
Non-Small-Cell Lung Cancer
Interventions
DRUG

Dabrafenib

Oral Dabrafenib 150 mg BID

DRUG

Trametinib

Oral Trametinib 2 mg QD

Sponsors
All Listed Sponsors
lead

Novartis Pharmaceuticals

INDUSTRY